Unusual to many early-stage Biotechnology companies, Ibex engages in a diverse and unique approach to Biotechnology, striving to discover, validate, and produce potential solutions to a multitude of medical challenges facing human and ecological health. Ibex has developed its programs "in-house" using ideas and techniques identified by its scientists and non-scientist managers. Ibex’s robust portfolio focuses on three primary areas: (1) Cancer and Non-Cancer Therapeutic antibodies / intrabody: Ibex is producing and developing antibodies targeting multiple cancers including breast, prostate, glioblastoma, and lung; (2) Cancer Gene Therapy: Ibex is developing a gene therapy that targets multiple cancer cells types including glioblastoma, melanoma, pancreatic, liver and cervical; (3) Diagnostic Antibodies: Ibex is developing an antibody to increasing the diagnostic reliability of various biopsies; (4) In-situ Regeneration Platform: Ibex is developing proprietary transcription factors to promote regeneration and treat various conditions such as Parkinson's Disease and other conditions within the human body.